Auris Medical initiated its first clinical trial with AM-111, its otoprotective compound for the treatment of acute sensorineural hearing loss. The double blind, randomised trial, which began on January 1, 2006 with patient enrolments at Munich and Berlin (Germany), will evaluate the safety of AM-111 in patients with acute sensorineural hearing loss from acute acoustic trauma. AM-111 was administered in the 24 hours following the New Year celebrations by transtympanic injection in the two participating study centres – the ENT departments of the Ludwig Maximilian University Munich and the Charité Berlin. The study’s lead investigator is Markus Suckfüll, MD.
